Skip to main content Back to Top
Advertisement

5/26/2021

Ondansetron Hydrochloride Injection

Products Affected - Description

    • Ondansetron injection, AuroMedics, 2 mg/mL, 2 mL vial, 25 count, NDC 55150-0125-02
    • Ondansetron injection, AuroMedics, 2 mg/mL, 20 mL vial, 1 count, NDC 55150-0126-20
    • Ondansetron injection, Fresenius Kabi, 2 mg/mL, 2 mL vial, 25 count, NDC 63323-0373-02
    • Ondansetron injection, Pfizer, 2 mg/mL, 20 mL vial, 1 count, NDC 00409-4759-01
    • Ondansetron injection, Sagent, 2 mg/mL, 20 mL vial, 1 count, NDC 25021-0782-20 - discontinued

Reason for the Shortage

    • Apotex has ondansetron injection available.
    • Athenex had ondansetron injection on shortage due to increased demand.
    • Avet had ondansetron on shortage due to increased demand. Avet discontinued ondansetron 2 mg/mL 2 mL vials in 10 count in late-2018.
    • AuroMedics did not provide a reason for the shortage.
    • Fosun has ondansetron injection available.
    • Fresenius Kabi did not provide a reason for the shortage.
    • Hikma did not provide a reason for the shortage.
    • Mylan Institutional did not provide a reason for the shortage.
    • Pfizer has ondansetron injection on shortage due to increased demand. The iSecure syringes were discontinued in January 2020.
    • Sagent discontinued ondansetron 20 mL vials in early-2021.
    • Novartis discontinued Zofran 20 mL vials in May 2018.

Available Products

    • Ondansetron injection, Apotex, 2 mg/mL, 2 mL vial, 25 count, NDC 60505-6130-05
    • Ondansetron injection, Athenex, 2 mg/mL, 2 mL vial, 25 count, NDC 70860-0776-02
    • Ondansetron injection, Athenex, 2 mg/mL, 20 mL vial, 1 count, NDC 70860-0777-20
    • Ondansetron injection, Avet Pharmaceuticals, 2 mg/mL, 2 mL vial, 25 count, NDC 23155-0547-42
    • Ondansetron injection, Avet Pharmaceuticals, 2 mg/mL, 20 mL vial, 1 count, NDC 23155-0549-31
    • Ondansetron injection, Fosun Pharma, 2 mg/mL, 2 mL vial, 25 count, NDC 72266-0123-01
    • Ondansetron injection, Fosun Pharma, 2 mg/mL, 20 mL vial, 1 count, NDC 72266-0124-01
    • Ondansetron injection, Fresenius Kabi, 2 mg/mL, 2 mL prefilled syringe, 24 count, NDC 76045-0103-20
    • Ondansetron injection, Fresenius Kabi, 2 mg/mL, 20 mL vial, 1 count, NDC 63323-0374-20
    • Ondansetron injection, Hikma, 2 mg/mL, 2 mL vial, 25 count, NDC 00641-6078-25
    • Ondansetron injection, Hikma, 2 mg/mL, 20 mL vial, 1 count, NDC 00641-6079-01
    • Ondansetron injection, Mylan Institutional, 2 mg/mL, 2 mL vial, 25 count, NDC 67457-0441-20
    • Ondansetron injection, Mylan Institutional, 2 mg/mL, 20 mL vial, 1 count, NDC 67457-0440-20
    • Ondansetron injection, Pfizer, 2 mg/mL, 2 mL vial, 25 count, NDC 00409-4755-03
    • Ondansetron injection, Sagent, 2 mg/mL, 2 mL vial, 25 count, NDC 25021-0777-02

Estimated Resupply Dates

    • AuroMedics has ondansetron 2 mg/mL 2 mL and 20 mL vials on intermittent back order and the company is releasing supplies as they become available.
    • Fresenius Kabi has short-dated ondansetron 2 mg/mL 2 mL vials available with an expiration date of < 1 month.
    • Pfizer has ondansetron 2 mg/mL 20 mL vials available in limited supply.

Updated

Updated May 26, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 8, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.